The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 180, 72 -78
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barber, A.
Right arrow Articles by Sentman, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barber, A.
Right arrow Articles by Sentman, C. L.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Ovarian Cancer

Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer1,2

Amorette Barber, Tong Zhang and Charles L. Sentman3

Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Ovarian cancer is one of the leading causes of cancer death in women and the development of novel therapies is needed to complement the standard treatment options such as chemotherapy and radiation. In this study, we show that treatment with T cells expressing a chimeric NKG2D receptor (chNKG2D) was able to lead to long-term, tumor-free survival in mice bearing established ovarian tumors. Tumor-free mice were able to reject a rechallenge with ovarian tumor cells 225 days after original tumor injection. In addition, chNKG2D T cell treatment induced specific host immune responses to ovarian tumor cells, including the development of both CD8+ and CD4+ T cell tumor-specific memory responses. The chNKG2D T cells reduced the ovarian tumor burden using both cytotoxic and cytokine-dependent pathways. Specifically, chNKG2D T cell expression of perforin, GM-CSF, and IFN-{gamma} were essential for complete antitumor efficacy.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Ovarian cancer has the highest mortality rate of the gynecologic malignancies and is the fifth leading cause of cancer death in women. T cell immunotherapy of cancer is an attractive option for therapy, as it produces a more selective targeting of tumor cells compared with chemotherapy or radiation. Adoptive transfer of tumor Ag-specific T cells has been shown to be a promising means for reducing tumor burden in multiple types of cancer, including melanoma and ovarian cancer (1, 2, 3). Ovarian tumor Ags for T cell therapy currently being investigated include Her2-neu, mesothelin, and the {alpha}-folate receptor (2, 4, 5). However, due to the existence of a MHC polymorphism within the population, many T cell therapies need to be individualized to each patient, basing the availability for therapy on the MHC alleles and the tumor Ags patients express. In addition, tumors can potentially down-regulate MHC class I expression and tumor cells often lack expression of costimulatory molecules, thus escaping recognition and activation of conventional CD8+ T cells (6, 7, 8).

Other prospective tumor-specific targets include the ligands for NKG2D, an activating receptor expressed primarily on NK cells and CD8+ T cells (9). NKG2D ligands are expressed on many different types of carcinoma and these molecules are not found on the cell surface of most normal tissues (9, 10). Most primary ovarian cancers express NKG2D ligands on the cell surface (11, 12, 13). To target these ligands, we designed chimeric NKG2D (chNKG2D)4 receptors, which consist of the NKG2D receptor fused to the cytoplasmic region of the CD3{zeta} chain, and expressed these receptors in T cells (12, 14, 15). We have shown that interaction of chNKG2D T cells with NKG2D ligand-expressing tumor cells leads to cytokine production from T cells and lysis of tumor cells, using either mouse or human T cells (12, 14, 15). The response of chNKG2D T cells is independent of MHC class I expression and dependent on NKG2D recognition of its ligands (14, 15). chNKG2D T cells inhibit the in vivo growth of tumor cells that express NKG2D ligands but not tumor cells that do not express NKG2D ligands (14). In addition, we have shown that when CD8+ T cells isolated from human ovarian cancer samples were transduced with chNKG2D, patient T cells secreted proinflammatory cytokines when cultured with autologous tumor cells, whereas the same tumor-infiltrating T cells transduced with a wild-type NKG2D (wtNKG2D) receptor did not respond to autologous tumor (12). Thus, expression of chNKG2D allows patient T cells to respond to their own tumor, indicating that chNKG2D receptors could be a potential immunotherapy for ovarian cancer. Our previous study has shown that treatment of an established ovarian tumor with chNKG2D T cells was able to significantly reduce the ovarian tumor burden in mice (12). This current study determined whether transfer of chNKG2D T cells increased survival in tumor-bearing mice and whether the tumor-surviving mice developed a protective host immune response to ovarian tumor Ags. In addition, we determined which effector mechanisms chNKG2D T cells required for therapeutic efficacy in vivo.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

Female C57BL/6 (B6) mice were purchased from the National Cancer Institute (Frederick, MD). IFN-{gamma}-deficient B6.129S7-Ifngtm1Ts/J (IFN-{gamma}–/–), FasL-deficient B6Smn.C3-Faslgld/J (FasL–/–), and perforin-deficient C57BL/6-Prf1tm1Sdz/J (Pfp–/–) mice were purchased from The Jackson Laboratory. GM-CSF knockout mice (GM-CSF–/–) on a C57BL/6 background were obtained from Dr. J. Whitsett (University of Cincinnati, Cincinnati, OH). Mice used were between 6 and 8 wk of age. All animal work was performed in the Dartmouth Medical School Animal Facility in accordance with institutional guidelines.

Injection of ID8-GFP cells and treatment of mice with genetically modified T cells

Mouse spleen cells were isolated, stimulated with Con A for 18 h (1 µg/ml), and transduced as previously described (14). Two days after transduction, T cells were selected in medium containing G418 (0.5 mg/ml) and 25 U/ml recombinant human IL-2 for 3 days. Viable cells were isolated using Histopaque-1083 (Sigma-Aldrich) and expanded for 2 days without G418 before functional analyses, as previously described (14). wtNKG2D and chNKG2D T cells consist of both CD8+ (~90%) and CD4+ (~10%) T cells. wtNKG2D and chNKG2D T cells were generated from B6 or immunodeficient mouse spleen cells, and similar cell yields and expression of NKG2D were obtained from the different strains. ID8-GFP cells were cultured as previously described (12). For survival studies, female B6 mice were injected with 2 or 5 x 106 ID8-GFP cells i.p. in 500 µl of PBS. wtNKG2D or chNKG2D modified T cells (5 x 106) were injected into mice i.p. 1, 2, and 3 wk after tumor injection. Mice were weighed at least once a week and were sacrificed when they had gained ~80% of their original body weight. For chNKG2D T cell mechanism studies, female B6 mice were injected with 2 x 106 ID8-GFP cells i.p. and treated 1 wk later with 5 x 106 wtNKG2D or chNKG2D modified T cells generated from B6, IFN-{gamma}–/–, GM-CSF–/–, or perforin–/– mice. Eight weeks after receiving the tumor injection, mice were sacrificed and a peritoneal wash was performed using 10 ml of PBS. The number of solid tumors on the peritoneum was counted. RBC in the peritoneal washes were lysed with ACK lysis buffer (0.15M NH4Cl, 1 mM KHCO3, 0.1 mM EDTA (pH 7.3)), the number of cells was counted, and the percentage of GFP+ cells was determined by flow cytometry. The absolute number of tumor cells in the peritoneal washes was determined by multiplying the percentage of GFP+ cells by the number of cells in the peritoneal wash. For the ID8-GFP tumor rechallenge, 106 ID8-GFP cells were injected i.p. into naive B6 or tumor-surviving mice. After 10 wk, mice were sacrificed and the absolute number of GFP+ cells in the peritoneal wash and number of solid tumors on the peritoneum were determined.

DNA isolation and nested PCR

Total DNA was isolated from spleen cells and peritoneal wash cells using a lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 0.1% Triton X-100, and 1 mg/ml proteinase K) at 5 x 106 cells/30 µl. Cells were lysed at 55°C overnight, and proteinase K was inactivated at 98°C for 10 min. These samples were directly used as template for nested PCR. For amplification of the tumor-specific gfp gene, primers were 5PFB (5'-ATCCTCTAGACTGCCGGATCG-3') and 3PFB (5'-CACATTGCCAAAAGACGGCAATATG-3'), which are specific for the retroviral vector pFB-neo (Stratagene). Cycling conditions consisted of a 3-min denaturation at 94°C, followed by 30 cycles of amplification (each cycle consisting of a 30-s denaturation at 94°C, a 30-s annealing at 56°C, and a 45-s extension at 72°C) and a final 3-min extension at 72°C. Nested amplifications used 1 µl of the primary PCR product as the template. The nested PCR primers were 5GFP (5'-CACATGAAGCAGCACGACTT-3') and 3GFP (5'-TGCTCAGGTAGTGGTTGTCG-3'), which are specific for the gfp gene. Nested cycling conditions were initial denaturation at 95°C for 3 min, 30 cycles of amplification (each cycle consisting of a 30-s denaturation at 95°C, a 45-s annealing at 59°C, and a 45-s extension at 72°C), and a final 3-min extension at 72°. For amplification of the chNKG2D gene, the pFB-neo primers described above were used to amplify the retroviral vector. Amplification conditions were similar to the pFB-neo conditions described above, only with a 45-s annealing at 56°C, and a 1-min, 30-s extension at 72°C. chNKG2D-specific nested primers were 5chNKG2D (5'-GGCGTCGACACCATGAGAGCAAAATTCAGCAGGAG-3') and 3chNKG2D (5'-GGCGCTCGAGTTACACCGCCCTTTTCATGCAGAT-3'). The chNKG2D pFB-neo cycling conditions were also used for this amplification. Each PCR was in a total volume of 20 µl and contained 200 µM each of dNTP, 1 U of Taq polymerase (NEB), and 0.2 µM primers. The PCR products were run on agarose gels and visualized by staining with SYBR Safe (Invitrogen Life Technologies).

Cytokine production in secondary stimulation cultures

Spleen cells (2.5 x 106) from naive or tumor-surviving mice were cultured with irradiated ID8 or RMA cells (2.5 x 105) for 72 h. Cell-free conditioned medium was assayed for IFN-{gamma} by ELISA using mouse Duoset ELISA kits (R&D Systems).

Intracellular cytokine detection by flow cytometry

Irradiated ID8 or RMA cells (1.5 x 105) were cultured with spleen cells (3 x 106) from naive B6 or tumor-surviving mice for 24 h. During the last 5 h of culture, 10 µg/ml brefeldin A was added to the wells (Sigma-Aldrich). Cells were then incubated with FcR block and cell surface stained with FITC-conjugated anti-CD8β (clone CT-CD8β; eBioscience) and allophycocyanin-conjugated anti-CD4 (clone RM4-5, BD Biosciences). Cells were fixed with 1% paraformaldehyde, permeabilized with 0.1% saponin, and stained with PE-conjugated anti-IFN-{gamma} (clone XMG12; eBioscience), PE-conjugated anti-TNF-{alpha} (clone MP6-XT22; BioSource International), or PE-conjugated anti-rat IgG1 isotype control (eBioscience). Cell fluorescence was monitored using a FACSCalibur cytometer (BD Biosciences).

Cytotoxicity by chNKG2D T cells

Lysis of ID8 cells was determined by 51Cr-release assays as previously described (14, 15).

Statistical analysis

Differences between groups were analyzed using the Student t test or ANOVA. Values of p < 0.05 were considered significant. For survival studies, Kaplan-Meier survival curves were plotted and analyzed using Prism software (GraphPad Software).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Adoptive transfer of chNKG2D T cells to ID8 tumor-bearing mice leads to long-term tumor-free survival

The murine ovarian cell line, ID8, was originally derived from spontaneously transformed B6 mouse ovarian surface epithelial cells and upon injection the tumor cells form ascites and solid tumors on the peritoneum in an immunocompetent host that mimics stage III/IV ovarian cancer (16). ID8 tumor cells express the NKG2D ligand Rae1 on the cell surface, but they do not express H-60 or Mult-1 (12). To determine whether treatment with chNKG2D T cells prolonged survival of mice with an established ID8 tumor burden, 2 or 5 x 106 ID8-GFP tumor cells were injected i.p. into mice, and the mice were given chNKG2D- or wtNKG2D-bearing T cells after 1, 2, and 3 wk. The survival of the mice was determined and mice were sacrificed when they had gained >80% of their original body weight due to ascites formation (Fig. 1, A and B). At both tumor doses, all of the chNKG2D T cell treated mice survived to 225 days, when a majority of the mice were removed from the experiment for analysis of immune function. Four mice at each tumor dose were allowed to continue until 325 days (Fig. 1A). At 325 days, all surviving mice were healthy. The median survival of the wtNKG2D T cell-treated mice was 97 days for those given 5 x 106 tumor cells and 120 days for mice given 2 x 106 tumor cells. Although wtNKG2D T cell-treated mice gained a significant amount of weight, chNKG2D T cell-treated mice did not have any unexpected weight gain or measurable ascites formation (Fig. 1B). In addition, the wtNKG2D T cell-treated mice had >100 solid tumors on the peritoneal lining when they were sacrificed, whereas the chNKG2D T cell-treated mice had no visible solid tumors.


Figure 1
View larger version (37K):
[in this window]
[in a new window]

  		FIGURE 1. Adoptive transfer of chNKG2D T cells to ovarian tumor-bearing mice leads to long-term tumor-free survival. A, A total of 2 x 106 (triangles) or 5 x 106 (squares) ID8-GFP cells were injected i.p. into B6 mice. After 1, 2, and 3 wk, mice were treated i.p. with either 5 x 106 wtNKG2D (wt, closed) or chNKG2D T cells (ch, open), and survival of the mice was measured (n = 12). Treatment with chNKG2D T cells significantly increased the survival of ID8-GFP-bearing mice compared with wtNKG2D-treated controls as indicated (*) (p < 0.001). A dotted line indicates that 4 of the 12 surviving mice from each tumor dose were allowed to survive 325 days, while the remaining 8 surviving mice were removed from the experiment on days 225 or 230 for further analysis. B, Mice were weighed at least once weekly and average weights of wtNKG2D- and chNKG2D-treated mice with 5 x 106 ID8-GFP cells are shown. chNKG2D T cell-treated mice gained significantly less weight than wtNKG2D T cell-treated mice as indicated (*, p < 0.001). C, Nested PCR for gfp was performed on the DNA from peritoneal wash cells of chNKG2D-treated surviving mice 230 days after original tumor challenge or naive mice. Contents in each lane are from: lanes 2–4, three surviving mice from 2 x 106 ID8-GFP challenge; lanes 5–7, three surviving mice from 5 x 106 ID8-GFP challenge; lanes 8–10, three naive mice; lane 11, water; lane 12, 10 ID8-GFP cells; lane 13, 1 ID8-GFP cell; lane 14, 100 ID8-GFP cells; lanes 1 and 15, 100-bp marker.

 
To address whether there was a low level of tumor burden remaining after chNKG2D T cell treatment, a nested PCR assay for a tumor-specific gene, gfp, was performed on peritoneal washes of three surviving mice 230 days after tumor injection. This PCR assay was able to detect at least one ID8-GFP cell equivalent in the PCR sample (Fig. 1C). No amplification of gfp was detected in the peritoneal wash cells or spleen cells of these mice (data not shown); therefore, chNKG2D T cell-treated surviving mice were ID8-GFP tumor cell-free 230 days after tumor injection. Thus, treatment with chNKG2D T cells led to long-term, tumor-free survival in a murine model of ovarian cancer.

Treatment with chNKG2D T cells induces a protective host antitumor immune response against ID8 tumor cells

It has been shown in other tumor models that survival of adoptively transferred T cells is correlated with antitumor in vivo efficacy (1, 17, 18). To determine whether chNKG2D T cells are being maintained long-term in vivo, a nested PCR assay specific for chNKG2D was performed. The spleens of chNKG2D T cell-treated surviving mice from Fig. 1A did not contain any chNKG2D T cells 230 days after tumor injection (Fig. 2A). This indicated that the chNKG2D T cells were not maintained long-term in vivo, although the mice remained long-term survivors. To determine whether chNKG2D T cell-treated surviving mice have developed host immune responses to ID8 cells, spleen cells from surviving mice or from naive B6 mice were cultured with ID8 cells, RMA cells (a B6-derived lymphoma), or with medium alone. Spleen cells from surviving mice secreted IFN-{gamma} when cultured with ID8 cells, but not with RMA cells or medium (Fig. 2B). Naive spleen cells did not secrete IFN-{gamma} when cultured in any of the conditions. These data indicate the development of a host immune response to ID8 Ags in tumor-surviving mice.


Figure 2
View larger version (42K):
[in this window]
[in a new window]

  		FIGURE 2. chNKG2D T cell-treated mice develop host immune responses to ID8 cells. A, PCR for the chNKG2D gene was performed on the DNA from spleen cells of chNKG2D T cell-treated surviving mice 230 days after original tumor challenge or naive B6 mice. Contents in each lane are from: lanes 2–4, three surviving mice from 2 x 106 ID8-GFP challenge; lanes 5–7, three surviving mice from 5 x 106 ID8-GFP challenge; lanes 8–10, three naive mice; lane 11, water; lane 12, 100 wtNKG2D T cells; lane 13, 100 chNKG2D T cells; lane 14, 10 chNKG2D T cells; lane 15, 1 chNKG2D T cell; lanes 1 and 16, 100-bp marker. B, A total of 230 days after tumor injection, spleen cells from three surviving mice from each group from Fig. 1A and three naive B6 mice were cultured with medium alone ({square}), ID8 cells ({blacksquare}), or RMA cells (Figure 2). Cell-free supernatants were analyzed for IFN-{gamma}. Significant differences are indicated (*, p < 0.001). Data are represented as mean + SD.

 
To characterize the development of a host T cell memory response to tumor Ags, intracellular cytokine analysis was performed on spleen cells from naive B6 or surviving mice 325 days after tumor injection (from Fig. 1A). IFN-{gamma} and TNF-{alpha} production was analyzed in spleen cells cultured with ID8 cells, RMA cells, or medium. A significant population of both CD8+ and CD4+ cells from surviving mice secreted IFN-{gamma} and TNF-{alpha} after coculture with ID8 cells, but not RMA cells or medium alone (Fig. 3). The percentage of CD8+ T cells secreting these cytokines was higher than the CD4+ T cell population. T cells from naive mice did not produce these cytokines. The percentage of CD8+ and CD4+ cells staining positive for TNF-{alpha} was high; however, we cannot rule out the possibility that some of the positive cells were due to cell surface binding of TNF-{alpha}.


Figure 3
View larger version (27K):
[in this window]
[in a new window]

  		FIGURE 3. Tumor-surviving mice develop host T cell memory responses to ID8 Ags. Spleen cells from chNKG2D T cell-treated mice surviving 325 days after tumor injection (n = 4 from each group from Fig. 1A) and naive B6 mice (n = 3) were cultured with medium ({square}), ID8 ({blacksquare}), or RMA (Figure 3). After 24 h, intracellular cytokine staining was performed for (A) IFN-{gamma} and (B) TNF-{alpha} production and gated on CD8+ or CD4+ T cells as indicated. T cells from tumor surviving mice produced significantly more IFN-{gamma} and TNF-{alpha} when cultured with ID8 cells than naive mice, as indicated (*, p < 0.05).

 
To test whether these memory responses were protective against a rechallenge with ID8 tumor cells, naive B6 and surviving mice (from each group in Fig. 1A) were challenged with 106 ID8-GFP cells i.p. After 10 wk, tumor burden was evaluated. Although naive B6 mice had a large number of tumor cells in the peritoneal wash and solid tumors on the peritoneum, 9 of 10 tumor-surviving mice completely rejected the rechallenge with tumor cells, and one mouse had a very low tumor burden (Fig. 4). Taken together, these data show that treatment with chNKG2D T cells led to the establishment of host antitumor immunity, with generation of both CD8+ and CD4+ ID8-specific T cells and protection against an ID8 tumor challenge.


Figure 4
View larger version (14K):
[in this window]
[in a new window]

  		FIGURE 4. ChNKG2D T cell treatment induces a protective antitumor immune response against ID8 tumor cells. ID8-GFP cells (106) were injected i.p. into chNKG2D T cell-treated surviving mice 225 days after original tumor challenge (n = 5 from each group from Fig. 1A) and naive B6 mice (n = 8). After 10 wk, tumor burden was determined by measuring the (A) absolute number of GFP+ cells in peritoneal washes or (B) counting the number of solid tumors on the peritoneal cavity. Five naive mice had over 100 solid tumors on the peritoneal cavity as indicated ({dagger}). Tumor burdens significantly different from naive mice are indicated (*, p < 0.001). Each data point represents an individual and the average of each group is shown.

 
ChNKG2D T cells require both cytotoxicity and cytokines for in vivo efficacy

We have shown that chNKG2D T cells can both secrete cytokines and lyse ovarian tumor cells in vitro; however, the molecular mechanisms chNKG2D T cells require to decrease ovarian tumor burden in vivo are unknown (12). Previous studies using anti-NKG2D-blocking Abs have shown that chNKG2D T cell lysis of tumor cells is dependent on NKG2D recognition (12, 14, 15). CD8+ T cells are able to use multiple cytotoxic pathways to directly kill tumor cells, including perforin and Fas-FasL. Which pathway effectively kills the tumor cell often depends on tumor cell susceptibility or resistance to these killing pathways. To first determine the in vitro mechanisms that chNKG2D T cells use to kill ID8 cells, chNKG2D T cells were derived from B6 mice, perforin–/–, or FasL–/– mice, and these cells were used as effectors against 51Cr-labeled ID8 cells (Fig. 5A). FasL–/– chNKG2D T cells were able to lyse ID8 cells as well as chNKG2D T cells from B6 mice. However, chNKG2D T cells deficient in perforin were unable to kill ID8 cells, indicating that chNKG2D T cells use perforin but not FasL to kill ID8 cells.


Figure 5
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 5. chNKG2D T cells require perforin and cytokines for in vivo efficacy. A, Lysis of ID8 cells by wtNKG2D (closed) or chNKG2D T cells (open) was measured at the indicated E:T ratios (1:1, 5:1, 25:1). chNKG2D T cells were derived from B6 (squares), perforin–/– (triangles), or FasL–/– (circles) mice. ChNKG2D T cells derived from B6 and FasL–/– mice lysed ID8 cells better than wtNKG2D T cells at all E:T ratios as indicated (*, p < 0.05). B and C, A total of 2 x 106 ID8-GFP cells were injected i.p. into B6 mice. After 7 days, mice received a single treatment of 5 x 106 wtNKG2D (B6 wt) or chNKG2D T cells i.p. chNKG2D T cells were derived from B6 (B6 ch), IFN{gamma}–/– (IFN-{gamma}–/– ch), GM-CSF–/– (GM-CSF–/– ch), or perforin–/– (Pfp–/– ch) mice as indicated. Tumor burden was determined after 8 wk by measuring the (B) absolute number of GFP+ cells in the peritoneal wash or (C) number of solid tumors on the peritoneum. Each data point represents an individual and the average of each group is shown. Data are from two separate experiments. **, Value of p < 0.01, compared with B6 wtNKG2D T cell treatment. §, Value of p < 0.01, compared with B6 chNKG2D T cell treatment.

 
Although chNKG2D T cells require expression of perforin to kill ID8 cells in vitro, the effector mechanisms required to eliminate tumor burden in vivo likely require both cytotoxicity and cytokine production. To test the in vivo effector mechanisms required for chNKG2D T cell antitumor activity, chNKG2D T cells were derived from B6-, perforin-, IFN-{gamma}-, or GM-CSF-deficient mice, and used to treat ID8-GFP tumor-bearing mice (Fig. 5, B and C). chNKG2D T cells deficient in perforin were able to significantly reduce the tumor burden compared with wtNKG2D T cell-treated mice, but not near as well as chNKG2D T cell-treated mice. Strikingly, chNKG2D T cells deficient in IFN-{gamma} were unable to reduce the tumor burden, illustrating the requirement of chNKG2D T cell-derived IFN-{gamma} for ovarian tumor reduction. In addition, chNKG2D T cell-derived GM-CSF also plays a role in tumor reduction, with GM-CSF-deficient T cells able to reduce the tumor burden partially, but not completely. The loss of efficacy by the knockout-derived chNKG2D T cells was not due to a deficiency in other effector functions, as the IFN-{gamma}–/– and GM-CSF–/– chNKG2D T cells were able to lyse ID8 cells as well as chNKG2D T cells from a B6 mouse. Perforin–/– and GM-CSF–/– chNKG2D T cells secreted similar amounts of IFN-{gamma} as B6-derived chNKG2D T cells when cultured with tumor cells (Fig. 6). Taken together, chNKG2D T cells require both cytotoxic function and cytokine secretion to eliminate an established ID8 tumor.


Figure 6
View larger version (21K):
[in this window]
[in a new window]

  		FIGURE 6. Gene-deficient chNKG2D T cells are not compromised in other effector functions. A, Lysis of ID8 cells by wtNKG2D (closed symbols) or chNKG2D T cells (open symbols) was measured at the indicated E:T ratios (1:1, 5:1, 25:1). chNKG2D T cells were derived from (A) B6 (squares) or IFN-{gamma}–/– (triangles) mice, or (B) B6 (squares) or GM-CSF–/– (diamonds) mice. The data are represented as mean + SD and are representative of two separate experiments. C, wtNKG2D or chNKG2D T cells were cultured with ID8 cells (wtNKG2D, {square}; chNKG2D, {blacksquare}) or with medium alone (wtNKG2D, Figure 6; chNKG2D, Figure 6). IFN-{gamma} was measured in cell-free supernatants after 24 h by ELISA. wtNKG2D and chNKG2D T cells were derived from (C) B6 or perforin–/– mice or (D) B6 or GM-CSF–/– mice as indicated. The data are represented as mean + SD and are representative of two separate experiments. The minimum detection level in this assay was 10 pg/ml and values below this are not shown.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
We have shown that treatment of an ovarian tumor with chNKG2D T cells leads to tumor-free survival. Additionally, the surviving mice developed a host memory response to ID8 tumor cells, and this host response was able to protect against a rechallenge with the same ovarian tumor cells. Complete tumor elimination by chNKG2D T cells required T cell-derived IFN-{gamma}, GM-CSF, and perforin, indicating that both cytotoxicity and cytokine secretion play a role in the in vivo response.

Currently, there is much research on using adoptive transfer of tumor Ag-specific T cells as a potential therapy for cancer. Initial trials involving transfer of tumor-infiltrating lymphocytes after nonmyeloablative chemotherapy in melanoma patients showed significant efficacy (19, 20, 21). However, many other recent clinical trials, including one in ovarian cancer using patient T cells genetically modified with a chimeric receptor specific for the {alpha}-folate receptor, were not as successful (2). Many clinical trials use T cells that are at a late effector phase due to long-term activation and expansion in vitro before transfer to the patients. However, it has recently been shown that treatment with fewer T cells that are at an earlier effector phase are more effective at decreasing tumor burden (1, 22, 23). The chNKG2D T cells are at an early effector phase based on cell surface staining (our unpublished data) and so may have stronger antitumor ability. Furthermore, many chimeric receptors engineered from single-chain Ab fragments can be immunogenic and thus rejected or inhibited by the host immune response (2, 24, 25). However, the extracellular portion of the chNKG2D receptor consists of the wtNKG2D receptor and so should not result in an immune response against the receptor.

Although chNKG2D T cells did not persist long-term in the tumor-surviving mice, this treatment did lead to the induction of host T cell memory responses to tumor Ags. The memory response that developed in these mice was protective against a tumor rechallenge, as mice that were injected with ID8 tumor cells 225 days after the original tumor challenge were able to reject the tumor rechallenge, illustrating the development of a functional memory response to ovarian tumor Ags. One indication that the development of host memory responses was specific is that both CD8+ and CD4+ T cells specifically produced IFN-{gamma} and TNF-{alpha} when cultured with ID8 cells, but not with B6-derived T cell lymphoma cells or medium alone. The development of host memory responses to tumor Ags may be important for tumor immunity, as immune responses to additional Ags would be beneficial if the tumor cells down-regulate NKG2D ligand expression or if not all of the tumor cells express NKG2D ligands. The percentages of cells that stained positive for TNF-{alpha} were surprisingly high, but it is possible that TNF-{alpha} that was secreted in the cell cultures bound to the cell surface receptors for TNF and represented both cell-bound and production of TNF-{alpha}.

Although T cells are able to kill tumor cells through multiple mechanisms, we showed that chNKG2D T cells depend solely on perforin to kill ID8 cells in vitro as chNKG2D T cells deficient in perforin expression were not able to lyse ID8 cells. Despite inability to kill in vitro, perforin–/– chNKG2D cells were still able to significantly, but not completely, reduce the ovarian tumor burden in vivo. However, chNKG2D T cell-derived IFN-{gamma} was essential for reducing the tumor burden as T cells deficient in this cytokine could not reduce the tumor burden. Although the exact mechanisms of chNKG2D T cells need to be further investigated, it has been shown in other tumor systems that IFN-{gamma} is able to have many antitumor effects such as activating macrophages, inhibiting angiogenesis, increasing MHC class I expression, promoting Ag presentation, and having antiproliferative effects on tumor cells (26, 27, 28, 29, 30). Multiple clinical trials have shown that administering IFN-{gamma} in combination with chemotherapy can be an effective treatment for ovarian cancer patients (31, 32, 33). In addition, chNKG2D T cell-derived GM-CSF, a molecule involved in the recruitment and activation of APCs, also had a role in tumor reduction. Ongoing clinical trials in ovarian cancer include administering GM-CSF to patients, and some trials that have been completed showed efficacy when GM-CSF was provided alone or in combination with other treatments such as chemotherapy (34, 35). Thus, both direct cytotoxicity and cytokine secretion by chNKG2D T cells are involved in complete antitumor efficacy. It is possible that chNKG2D T cells not only directly kill tumor cells, thereby decreasing the tumor burden and releasing tumor Ags, but also activate and recruit APCs, such as dendritic cells and macrophages, helping to initiate host immune response to additional tumor Ags, and lead to the development of a host immune response that is involved in eliminating tumor cells and results in the development of T cell memory responses. In addition, the myriad of suppressor cells and molecules found in the tumor environment, such as IDO, programmed death-1 ligand-1, myeloid suppressor cells, and regulatory T cells, often suppress T cell responses that develop in ovarian cancer patients (36, 37, 38, 39). The proinflammatory environment that chNKG2D T cells create around the tumor may also be acting to relieve these immunosuppressive mechanisms.

Ovarian cancer is difficult to treat and has the highest mortality rate of all the cancers of the female reproductive tract. This is partially due to the lack of early symptoms and frequent diagnosis at a late stage of disease. Over 50% of cases are found when a patient is at least in stage III of disease, when the cancer has metastasized to the peritoneal lining and/or the lymph nodes. The ID8 tumor model used in this study recapitulates many aspects of ovarian cancer including the formation of both ascites and solid tumors on the peritoneum. Treatment of an established ID8 tumor with chNKG2D T cells led to tumor-free survival and the development of functional host T cell memory responses to ovarian tumor Ags.


   Acknowledgments
 
We thank Dr. Jeff Whitsett (University of Cincinnati, Cincinnati, OH) for providing GM-CSF–/– mice and Dr. Katherine F. Roby (University of Kansas Medical Center, Kansas City, KS) for the ID8 cells.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by grants from The Hitchcock Foundation, the Department of Microbiology and Immunology, Dartmouth Medical School, National Institutes of Health (AI 07363), and a Leukemia and Lymphoma Society Special Fellowship (to T.Z.). Back

2 The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the Leukemia and Lymphoma Society. Back

3 Address correspondence and reprint requests to Dr. Charles L. Sentman, Department of Microbiology and Immunology, Dartmouth Medical School, 6W Borwell Building, One Medical Center Drive, Lebanon, NH 03756. E-mail address: charles.sentman{at}dartmouth.edu Back

4 Abbreviations used in this paper: chNKG2D, chimeric NKG2D; wtNKG2D, wild-type NKG2D. Back

Received for publication September 4, 2007. Accepted for publication October 17, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Gattinoni, L., D. J. Powell, Jr, S. A. Rosenberg, N. P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393. [Medline]
  2. Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12: 6106-6115. [Abstract/Free Full Text]
  3. June, C. H.. 2007. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117: 1466-1476. [Medline]
  4. Hung, C. F., Y. C. Tsai, L. He, T. C. Wu. 2007. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther. 14: 921-929. [Medline]
  5. Disis, M. L., T. A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M. A. Cheever, K. L. Knutson, K. Schiffman. 2002. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20: 2624-2632. [Abstract/Free Full Text]
  6. Rabinovich, G. A., D. Gabrilovich, E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296. [Medline]
  7. Inman, B. A., X. Frigola, H. Dong, E. D. Kwon. 2007. Costimulation, coinhibition and cancer. Curr. Cancer Drug Targets 7: 15-30. [Medline]
  8. Norell, H., M. Carlsten, T. Ohlum, K. J. Malmberg, G. Masucci, K. Schedvins, W. Altermann, D. Handke, D. Atkins, B. Seliger, R. Kiessling. 2006. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res. 66: 6387-6394. [Abstract/Free Full Text]
  9. Raulet, D. H.. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3: 781-790. [Medline]
  10. Sentman, C. L., M. A. Barber, A. Barber, T. Zhang. 2006. NK cell receptors as tools for cancer immunotherapy. Adv. Cancer Res. 95: 249-292. [Medline]
  11. Pende, D., P. Rivera, S. Marcenaro, C. C. Chang, R. Biassoni, R. Conte, M. Kubin, D. Cosman, S. Ferrone, L. Moretta, A. Moretta. 2002. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62: 6178-6186. [Abstract/Free Full Text]
  12. Barber, A., T. Zhang, L. R. DeMars, J. Conejo-Garcia, K. F. Roby, C. L. Sentman. 2007. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 67: 5003-5008. [Abstract/Free Full Text]
  13. Carlsten, M., N. K. Bjorkstrom, H. Norell, Y. Bryceson, T. van Hall, B. C. Baumann, M. Hanson, K. Schedvins, R. Kiessling, H. G. Ljunggren, K. J. Malmberg. 2007. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67: 1317-1325. [Abstract/Free Full Text]
  14. Zhang, T., B. A. Lemoi, C. L. Sentman. 2005. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106: 1544-1551. [Abstract/Free Full Text]
  15. Zhang, T., A. Barber, C. L. Sentman. 2006. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 66: 5927-5933. [Abstract/Free Full Text]
  16. Roby, K. F., C. C. Taylor, J. P. Sweetwood, Y. Cheng, J. L. Pace, O. Tawfik, D. L. Persons, P. G. Smith, P. F. Terranova. 2000. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591. [Abstract/Free Full Text]
  17. Robbins, P. F., M. E. Dudley, J. Wunderlich, M. El-Gamil, Y. F. Li, J. Zhou, J. Huang, D. J. Powell, Jr, S. A. Rosenberg. 2004. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173: 7125-7130. [Abstract/Free Full Text]
  18. Zhou, J., X. Shen, J. Huang, R. J. Hodes, S. A. Rosenberg, P. F. Robbins. 2005. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175: 7046-7052. [Abstract/Free Full Text]
  19. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. [Abstract/Free Full Text]
  20. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357. [Abstract/Free Full Text]
  21. Muranski, P., A. Boni, C. Wrzesinski, D. E. Citrin, S. A. Rosenberg, R. Childs, N. P. Restifo. 2006. Increased intensity lymphodepletion and adoptive immunotherapy–how far can we go?. Nat. Clin. Pract. Oncol. 3: 668-681. [Medline]
  22. Gattinoni, L., C. A. Klebanoff, D. C. Palmer, C. Wrzesinski, K. Kerstann, Z. Yu, S. E. Finkelstein, M. R. Theoret, S. A. Rosenberg, N. P. Restifo. 2005. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115: 1616-1626. [Medline]
  23. Huang, J., H. T. Khong, M. E. Dudley, M. El-Gamil, Y. F. Li, S. A. Rosenberg, P. F. Robbins. 2005. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28: 258-267. [Medline]
  24. Park, J. R., D. L. Digiusto, M. Slovak, C. Wright, A. Naranjo, J. Wagner, H. B. Meechoovet, C. Bautista, W. C. Chang, J. R. Ostberg, M. C. Jensen. 2007. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15: 825-833. [Medline]
  25. Lamers, C. H., S. Sleijfer, A. G. Vulto, W. H. Kruit, M. Kliffen, R. Debets, J. W. Gratama, G. Stoter, E. Oosterwijk. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24: e20-e22. [Free Full Text]
  26. Schroder, K., P. J. Hertzog, T. Ravasi, D. A. Hume. 2004. Interferon-{gamma}: an overview of signals, mechanisms and functions. J. Leukocyte Biol. 75: 163-189. [Abstract/Free Full Text]
  27. Dunn, G. P., C. M. Koebel, R. D. Schreiber. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6: 836-848. [Medline]
  28. Blankenstein, T., Z. Qin. 2003. The role of IFN-{gamma} in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr. Opin. Immunol. 15: 148-154. [Medline]
  29. Beatty, G., Y. Paterson. 2001. IFN-{gamma}-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-{gamma}. J. Immunol. 166: 2276-2282. [Abstract/Free Full Text]
  30. Wigginton, J. M., E. Gruys, L. Geiselhart, J. Subleski, K. L. Komschlies, J. W. Park, T. A. Wiltrout, K. Nagashima, T. C. Back, R. H. Wiltrout. 2001. IFN-{gamma} and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 108: 51-62. [Medline]
  31. Marth, C., G. H. Windbichler, H. Hausmaninger, E. Petru, K. Estermann, A. Pelzer, E. Mueller-Holzner. 2006. Interferon-{gamma} in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gynecol. Cancer 16: 1522-1528. [Medline]
  32. Windbichler, G. H., H. Hausmaninger, W. Stummvoll, A. H. Graf, C. Kainz, J. Lahodny, U. Denison, E. Muller-Holzner, C. Marth. 2000. Interferon-{gamma} in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer 82: 1138-1144. [Medline]
  33. Pujade-Lauraine, E., J. P. Guastalla, N. Colombo, P. Devillier, E. Francois, P. Fumoleau, A. Monnier, M. Nooy, L. Mignot, R. Bugat, et al 1996. Intraperitoneal recombinant interferon {gamma} in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin. Oncol. 14: 343-350. [Abstract/Free Full Text]
  34. Baur, M., E. Schernhammer, M. Gneist, P. Sevelda, P. Speiser, M. Hudec, C. Dittrich. 2005. Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. Br. J. Cancer 92: 1019-1025. [Medline]
  35. Kurbacher, C. M., J. A. Kurbacher, E. M. Cramer, K. Rhiem, P. K. Mallman, R. Reichelt, U. Reinhold, U. Stier, I. A. Cree. 2005. Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology 19: 23-26.
  36. Hamanishi, J., M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, et al 2007. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 104: 3360-3365. [Abstract/Free Full Text]
  37. Yang, R., Z. Cai, Y. Zhang, W. H. t. Yutzy, K. F. Roby, R. B. Roden. 2006. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 66: 6807-6815. [Abstract/Free Full Text]
  38. Zou, W.. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274. [Medline]
  39. Zou, W.. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307. [Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. Barber, A. Rynda, and C. L. Sentman
Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment
J. Immunol., December 1, 2009; 183(11): 6939 - 6947.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Barber and C. L. Sentman
Chimeric NKG2D T Cells Require Both T Cell- and Host-Derived Cytokine Secretion and Perforin Expression to Increase Tumor Antigen Presentation and Systemic Immunity
J. Immunol., August 15, 2009; 183(4): 2365 - 2372.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Nesbeth, U. Scarlett, J. Cubillos-Ruiz, D. Martinez, X. Engle, M.-J. Turk, and J. R. Conejo-Garcia
CCL5-Mediated Endogenous Antitumor Immunity Elicited by Adoptively Transferred Lymphocytes and Dendritic Cell Depletion
Cancer Res., August 1, 2009; 69(15): 6331 - 6338.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Krockenberger, Y. Dombrowski, C. Weidler, M. Ossadnik, A. Honig, S. Hausler, H. Voigt, J. C. Becker, L. Leng, A. Steinle, et al.
Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2D
J. Immunol., June 1, 2008; 180(11): 7338 - 7348.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barber, A.
Right arrow Articles by Sentman, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barber, A.
Right arrow Articles by Sentman, C. L.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Ovarian Cancer

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS